{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:37:42Z","timestamp":1794008262476,"version":"4.8.0"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K\/AKT\/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K\/AKT\/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K\/AKT\/mTOR pathway in drug resistance, the development of PI3K\/AKT\/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer.<\/jats:p>","DOI":"10.3389\/fphar.2021.628690","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:33:31Z","timestamp":1615768411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":375,"title":["Activation of PI3K\/AKT\/mTOR Pathway Causes Drug Resistance in Breast Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Chao","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceshi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1158\/2326-6066.cir-14-0095","article-title":"Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway","volume":"2","author":"Abu-Eid","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/s1470-2045(14)70138-x","article-title":"Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Andr\u00e9","year":"2014","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1158\/0008-5472.can-10-3795","article-title":"p95HER2 and breast cancer","volume":"71","author":"Arribas","year":"2011","journal-title":"Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/jco.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/s1470-2045(17)30376-5","article-title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Baselga","year":"2017","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"LBA1006","DOI":"10.1007\/s10549-018-4697-y","article-title":"Phase III study of taselisib (GDC0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary analysis from SANDPIPER","volume":"36","author":"Baselga","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/cancers11040435","article-title":"PTEN as a prognostic\/predictive biomarker in cancer: an unfulfilled promise?","volume":"11","author":"Bazzichetto","year":"2019","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1186\/bcr3606","article-title":"PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients","volume":"16","author":"Beelen","year":"2014","journal-title":"Breast Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ygyno.2017.10.003","article-title":"PARP inhibitors: clinical utility and possibilities of overcoming resistance","volume":"147","author":"Bitler","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1080\/15384047.2014.1002693","article-title":"PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition","volume":"16","author":"Brady","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"x27","DOI":"10.1093\/annonc\/mdz280","article-title":"Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors","volume":"30","author":"Brand\u00e3o","year":"2019","journal-title":"Ann. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10549-010-1232-1","article-title":"The PI3 kinase\/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells","volume":"129","author":"Br\u00fcnner-Kubath","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"B17","doi-asserted-by":"publisher","first-page":"9817","DOI":"10.1074\/jbc.M010840200","article-title":"Phosphatidylinositol 3-kinase\/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance","volume":"276","author":"Campbell","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s12094-019-02163-2","article-title":"The potential markers of endocrine resistance among HR+\/HER2+ breast cancer patients","volume":"22","author":"Chen","year":"","journal-title":"Clin. Transl Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"117816","DOI":"10.1016\/j.lfs.2020.117816","article-title":"Novel PI3K\/Akt\/mTOR pathway inhibitors plus radiotherapy: strategy for non-small cell lung cancer with mutant RAS gene","volume":"255","author":"Chen","year":"","journal-title":"Life Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fcell.2020.00232","article-title":"ANXA6 contributes to radioresistance by promoting autophagy via inhibiting the PI3K\/AKT\/mTOR signaling pathway in nasopharyngeal carcinoma","volume":"8","author":"Chen","year":"","journal-title":"Front. Cell Dev. Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cancergencyto.2008.07.005","article-title":"PIK3CA gene mutations in breast carcinoma in Malaysian patients","volume":"187","author":"Ching-Shian Leong","year":"2008","journal-title":"Cancer Genet. Cytogenet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10911-012-9264-2","article-title":"Targeting the PI3K\/Akt\/mTOR pathway for breast cancer therapy","volume":"17","author":"Cidado","year":"2012","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-010-1108-4","article-title":"Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy","volume":"124","author":"Coughlin","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"B24","first-page":"733","article-title":"A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK","volume":"7","author":"Dey","year":"2015","journal-title":"Am. J. Transl Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7150\/ijbs.32625","article-title":"Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K\/AKT signaling pathway","volume":"10","author":"Dong","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fimmu.2018.00575","article-title":"Molecular mechanisms of human disease mediated by oncogenic and primary immunodeficiency mutations in class IA phosphoinositide 3-kinases","volume":"9","author":"Dornan","year":"2018","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.1158\/0008-5472.can-08-1740","article-title":"Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235","volume":"68","author":"Eichhorn","year":"2008","journal-title":"Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10549-014-3239-5","article-title":"A preclinical evaluation of the PI3K alpha\/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib","volume":"149","author":"Elster","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.ccr-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s11033-019-05114-w","article-title":"SRT1720, a potential sensitizer for radiotherapy and cytotoxicity effects of NVB-BEZ235 in metastatic breast cancer cells","volume":"214","author":"Fatehi","year":"2018","journal-title":"Mol. Biol. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1535-7163.mct-13-0865","article-title":"Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials","volume":"13","author":"Fritsch","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-019-05239-3","article-title":"Regulation of AKT phosphorylation by GSK3\u03b2 and PTEN to control chemoresistance in breast cancer","volume":"176","author":"Gao","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"B33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2174\/187152012799015002","article-title":"Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance","volume":"12","author":"Gayle","year":"2012","journal-title":"Anticancer Agents Med. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"16208","DOI":"10.1038\/s41598-020-73249-z","article-title":"The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells","volume":"10","author":"Glorieux","year":"2020","journal-title":"Sci. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/14737140.2018.1458613","article-title":"Olaparib for the treatment of breast cancer","volume":"18","author":"Griguolo","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10555-016-9637-x","article-title":"PI3K\/AKT\/mTOR: role in breast cancer progression, drug resistance, and treatment","volume":"35","author":"Guerrero-Zotano","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12282-017-0772-1","article-title":"Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications","volume":"25","author":"Hanamura","year":"2018","journal-title":"Breast Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.can-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","article-title":"Suppression of insulin feedback enhances the efficacy of PI3K inhibitors","volume":"560","author":"Hopkins","year":"2018","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1158\/1078-0432.ccr-15-2764","article-title":"Combined inhibition of both p110\u03b1 and p110\u03b2 isoforms of phosphatidylinositol 3-kinase is required for sustained therapeutic effect in PTEN-deficient, ER(+) breast cancer","volume":"23","author":"Hosford","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","article-title":"Talazoparib: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2020","DOI":"10.1038\/cddis.2015.363","article-title":"Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells","volume":"6","author":"Hu","year":"2015","journal-title":"Cell Death Dis."},{"key":"B43","first-page":"6055","article-title":"PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer","volume":"11","author":"Huang","year":"2019","journal-title":"Am. J. Transl Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/s1470-2045(15)00051-0","article-title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","volume":"16","author":"Hurvitz","year":"2015","journal-title":"Lancet Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.cd-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov."},{"key":"B46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.can-16-2653","article-title":"Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4\/6 inhibition in ER-positive breast cancer","volume":"77","author":"Jansen","year":"2017","journal-title":"Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"108800","DOI":"10.1016\/j.biopha.2019.108800","article-title":"Chemoresistance mechanisms of breast cancer and their countermeasures","volume":"114","author":"Ji","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s1470-2045(19)30817-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial","volume":"21","author":"Jones","year":"2020","journal-title":"Lancet Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature13948","article-title":"Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor","volume":"518","author":"Juric","year":"2015","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov."},{"key":"B52","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3109\/07388551.2015.1015957","article-title":"Molecular mechanisms of drug resistance and its reversal in cancer","volume":"36","author":"Kartal-Yandim","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/annonc\/mdp304","article-title":"Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines","volume":"21","author":"Kataoka","year":"2010","journal-title":"Ann. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist. Updat"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2018.1417384","article-title":"PI3K inhibition to overcome endocrine resistance in breast cancer","volume":"27","author":"Keegan","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/s1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/s1470-2045(16)00106-6","article-title":"Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Krop","year":"2016","journal-title":"Lancet Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1021\/acsnano.6b01600","article-title":"Combining immune checkpoint inhibitors and kinase-inhibiting supramolecular therapeutics for enhanced anticancer efficacy","volume":"10","author":"Kulkarni","year":"2016","journal-title":"ACS Nano"},{"key":"B59","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nri3536","article-title":"T-bet: a bridge between innate and adaptive immunity","volume":"13","author":"Lazarevic","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","article-title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer","volume":"275","author":"Li","year":"1997","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12943-018-0862-5","article-title":"Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/1535-7163.mct-19-0261","article-title":"Transgelin 2 promotes paclitaxel resistance, migration, and invasion of breast cancer by directly interacting with PTEN and activating PI3K\/Akt\/GSK-3\u03b2 pathway","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"B64","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s10637-018-0563-3","article-title":"PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation","volume":"36","author":"Liu","year":"2018","journal-title":"Invest. New Drugs"},{"key":"B65","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2017.08.020","article-title":"Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: a randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)","volume":"85","author":"Loibl","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-018-0694-6","article-title":"14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin \u03b1v\u03b23 and activating FAK\/PI3K\/AKT signaling","volume":"37","author":"Luo","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1158\/1535-7163.mct-11-0474","article-title":"Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor","volume":"11","author":"Maira","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.2174\/1871520618666180911142259","article-title":"A review on the role of VEGF in tamoxifen resistance","volume":"18","author":"Mansouri","year":"2018","journal-title":"Anticancer Agents Med. Chem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","article-title":"Alpelisib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B70","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3389\/fonc.2020.00968","article-title":"Akt inhibition is associated with favorable immune profile changes within the tumor microenvironment of hormone receptor positive, HER2 negative breast cancer","volume":"10","author":"Marks","year":"2020","journal-title":"Front. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/annonc\/mdw562","article-title":"A randomized adaptive phase II\/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)","volume":"28","author":"Mart\u00edn","year":"2017","journal-title":"Ann. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11033-019-05114-w","article-title":"The beneficial role of SIRT1 activator on chemo- and radiosensitization of breast cancer cells in response to IL-6","volume":"47","author":"Masoumi","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"B73","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1078-0432.ccr-16-0134","article-title":"A phase Ib study of alpelisib (BYL719), a PI3k\u03b1-specific inhibitor, with letrozole in ER+\/HER2- metastatic breast cancer","volume":"23","author":"Mayer","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/jco.2013.54.0518","article-title":"Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"32","author":"Mayer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/1535-7163.mct-17-0537","article-title":"Combined inhibition of mTOR and CDK4\/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer","volume":"17","author":"Michaloglou","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1200\/jco.2010.34.4879","article-title":"Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer","volume":"29","author":"Miller","year":"","journal-title":"J. Clin. Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.cd-11-0101","article-title":"ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer","volume":"1","author":"Miller","year":"","journal-title":"Cancer Discov."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1172\/jci41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J. Clin. Invest."},{"key":"B79","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/bcr3039","article-title":"Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer","volume":"13","author":"Miller","year":"","journal-title":"Breast Cancer Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.2147\/cmar.s202965","article-title":"A systematic literature review of the prognostic and predictive value of PIK3CA mutations in HR(+)\/HER2(\u2212) metastatic breast cancer","volume":"20","author":"Mollon","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/bctt.s60696","article-title":"PI3K mutations in breast cancer: prognostic and therapeutic implications","volume":"7","author":"Mukohara","year":"2015","journal-title":"Breast Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s11864-019-0651-4","article-title":"The role of CDK4\/6 inhibitors in breast cancer","volume":"20","author":"Murphy","year":"2019","journal-title":"Curr. Treat. Options. Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/1871520616666160502122724","article-title":"Breast cancer: current molecular therapeutic targets and new players","volume":"17","author":"Nagini","year":"2017","journal-title":"Anticancer Agents Med. Chem."},{"key":"B84","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1021\/jm4003632","article-title":"Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a \u03b2-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity","volume":"56","author":"Ndubaku","year":"2013","journal-title":"J. Med. Chem."},{"key":"B85","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Network","year":"2012","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.4161\/cbt.8.24.10131","article-title":"Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance","volume":"8","author":"No","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.cd-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O\u2019Leary","year":"2018","journal-title":"Cancer Discov."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.2174\/0929867325666171129215610","article-title":"Overview on anticancer drug design and development","volume":"25","author":"Olgen","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"B89","doi-asserted-by":"publisher","first-page":"969","DOI":"10.18632\/oncotarget.27503","article-title":"Targeting PI3K\u03b2 alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss","volume":"11","author":"Owusu-Brackett","year":"2020","journal-title":"Oncotarget"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1158\/1078-0432.ccr-09-2828","article-title":"Predictive biomarkers of sensitivity to the phosphatidylinositol 3\u2019 kinase inhibitor GDC-0941 in breast cancer preclinical models","volume":"16","author":"O\u2019Brien","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1158\/1078-0432.ccr-13-2769","article-title":"Targeting PI3K\/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT","volume":"20","author":"O\u2019Brien","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells","volume":"177","author":"Patton","year":"2006","journal-title":"J. Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1758835919833519","DOI":"10.1177\/1758835919833519","article-title":"HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance","volume":"11","author":"Pernas","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1200\/jco.2014.56.2439","article-title":"Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial","volume":"33","author":"Pogue-Geile","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.canlet.2019.08.008","article-title":"Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K\/AKT pathway","volume":"464","author":"Qiu","year":"2019","journal-title":"Cancer Lett."},{"key":"B96","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-013-2529-7","article-title":"Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen","volume":"139","author":"Ramirez-Ardila","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"B97","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-011-1572-5","article-title":"Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer","volume":"128","author":"Razis","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1200\/jco.2013.53.8272","article-title":"Mutational analysis of PI3K\/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study","volume":"32","author":"Sabine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"R21","DOI":"10.1186\/bcr2833","article-title":"Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer","volume":"13","author":"Sanchez","year":"2011","journal-title":"Breast Cancer Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/jco.2015.63.9179","article-title":"Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer","volume":"34","author":"Schmid","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/cancers12020467","article-title":"Dual PI3K\/mTOR inhibitor NVP-BEZ235 enhances radiosensitivity of head and neck squamous cell carcinoma (HNSCC) cell lines due to suppressed double-strand break (DSB) repair by non-homologous end joining","volume":"12","author":"Sch\u00f6tz","year":"2020","journal-title":"Cancers"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1172\/jci66343","article-title":"RSK3\/4 mediate resistance to PI3K pathway inhibitors in breast cancer","volume":"123","author":"Serra","year":"2013","journal-title":"J. Clin. Invest."},{"key":"B103","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.15190\/d.2019.4","article-title":"Immunotherapy for breast cancer: first FDA approved regimen","volume":"7","author":"Soare","year":"2019","journal-title":"Discoveries"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/1078-0432.ccr-14-2993","article-title":"PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance","volume":"21","author":"Stern","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.18632\/oncotarget.1952","article-title":"Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers","volume":"5","author":"Sun","year":"2014","journal-title":"Oncotarget"},{"key":"B107","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bcp.2018.10.005","article-title":"PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome","volume":"162","author":"Tapodi","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"35767","DOI":"10.1074\/jbc.M507075200","article-title":"Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress","volume":"280","author":"Tapodi","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B109","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/sj.leu.2404523","article-title":"Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase\/Akt signal transduction network in human acute myelogenous leukemia blasts","volume":"21","author":"Tazzari","year":"2007","journal-title":"Leukemia"},{"key":"B110","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1158\/2159-8290.cd-nb2018-008","article-title":"First PARP inhibitor ok\u2019d for breast cancer","volume":"8","author":"Tompa","year":"2018","journal-title":"Cancer Discov."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e0116747","DOI":"10.1371\/journal.pone.0116747","article-title":"A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance","volume":"10","author":"Tsou","year":"2015","journal-title":"PLoS One"},{"key":"B112","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1182\/blood-2014-05-578583","article-title":"Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy","volume":"124","author":"van der Waart","year":"2014","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/s0006-2952(03)00077-7","article-title":"Decrease of the inflammatory response and induction of the Akt\/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock","volume":"65","author":"Veres","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1124\/jpet.104.065151","article-title":"Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice","volume":"310","author":"Veres","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"x12","DOI":"10.1093\/annonc\/mdz381","article-title":"Efficacy of PI3K inhibitors in advanced breast cancer","volume":"30","author":"Verret","year":"2019","journal-title":"Ann. Oncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","article-title":"CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors","volume":"26","author":"Vora","year":"2014","journal-title":"Cancer Cell"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/annonc\/mdw320","article-title":"Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study","volume":"27","author":"Vuylsteke","year":"2016","journal-title":"Ann. Oncol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.3892\/or.2016.4730","article-title":"Osthole shows the potential to overcome P-glycoprotein-mediated multidrug resistance in human myelogenous leukemia K562\/ADM cells by inhibiting the PI3K\/Akt signaling pathway","volume":"35","author":"Wang","year":"","journal-title":"Oncol. Rep."},{"key":"B119","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1038\/onc.2015.406","article-title":"PI3K-p110\u03b1 mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers","volume":"35","author":"Wang","year":"","journal-title":"Oncogene"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/cancers12051278","article-title":"Radiosensitising cancer using phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKT) or mammalian target of rapamycin (mTOR) inhibitors","volume":"12","author":"Wanigasooriya","year":"2020","journal-title":"Cancers"},{"key":"B121","doi-asserted-by":"publisher","first-page":"13057","DOI":"10.1073\/pnas.0802655105","article-title":"PTEN-deficient cancers depend on PIK3CB","volume":"105","author":"Wee","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B122","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1200\/jco.2011.38.3331","article-title":"Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11912-020-00917-8","article-title":"Sequencing endocrine therapy for metastatic breast cancer: what do we do after disease progression on a CDK4\/6 inhibitor?","volume":"22","author":"Xi","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"B124","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.coph.2015.05.016","article-title":"Drugging PI3K in cancer: refining targets and therapeutic strategies","volume":"23","author":"Yap","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv. Ther."},{"key":"B126","doi-asserted-by":"publisher","first-page":"68641","DOI":"10.18632\/oncotarget.19817","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"B127","doi-asserted-by":"publisher","first-page":"14831","DOI":"10.1007\/s13277-016-5381-7","article-title":"Addition of the p110\u03b1 inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer","volume":"37","author":"Zhang","year":"","journal-title":"Tumour Biol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"13037","DOI":"10.1002\/jcb.28574","article-title":"Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition","volume":"120","author":"Zhang","year":"2019","journal-title":"J. Cell Biochem"},{"key":"B129","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.molcel.2016.04.023","article-title":"Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of akt","volume":"62","author":"Zhang","year":"","journal-title":"Mol. Cell"},{"key":"B130","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-019-1112-1","article-title":"The PI3K subunits, P110\u03b1 and P110\u03b2 are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"key":"B131","doi-asserted-by":"publisher","first-page":"248","DOI":"10.5306\/wjco.v5.i3.248","article-title":"Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer","volume":"5","author":"Zhao","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1010428317697562","DOI":"10.1177\/1010428317697562","article-title":"Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K\/AKT\/mTOR signaling pathway","volume":"39","author":"Zhong","year":"2017","journal-title":"Tumour Biol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3109\/1061186x.2014.936870","article-title":"3-Methyladenine can depress drug efflux transporters via blocking the PI3K-AKT-mTOR pathway thus sensitizing MDR cancer to chemotherapy","volume":"22","author":"Zou","year":"2014","journal-title":"J. Drug Target."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.628690\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:33:36Z","timestamp":1615768416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.628690\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":133,"alternative-id":["10.3389\/fphar.2021.628690"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.628690","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"article-number":"628690"}}